The Potential of Porang (Amorphophallus muelleri Blume) Flour and Porang Flour Formulation as an Anti-Diabetes Type-2 Agent

Abstract

Porang (Amorphophallus muelleri Blume) is a source of glucomannan in Indonesia, and a potential agent for diabetes mellitus treatment, apart from konjac. This study aims to determine the potential of porang flour formulation as a therapeutic agent for diabetes mellitus, especially type-2 diabetes mellitus. Soluble fiber, water absorption capacity(WAC), disintegration time, and viscosity of porang flour (PF) and porang flour formulation (PFF: consist of 85% porang flour, 1.03% k-carrageenan flour, 12% inulin flour, and 1.97% modified cassava flour (MOCAF)) were scrutinized. Twenty-eight male albino Wistar rats were randomly split into seven experimental groups. Five groups consisting of diabetic rats were treated using porang flour (300 mg/kg bw); low, middle, and high doses of porang flour formulation (100, 300, 500 mg/kg bw, respectively); and metformin (51.38 mg/kg bw). The rest were normal, and the diabetic (DM) control group. PF, PFF, and metformin were orally administered to the streptozotocin-induced diabetic rats per day for four weeks of the experiment. Fasting plasma glucose (FPG), Malondialdehyde (MDA) level, lipid profile, aspartate aminotransferase (AST), and alanine transaminase (ALT) levels of the blood plasma were measured, while the pancreas was used for immunohistochemical study and β-cells quantification. ANOVA was employed to analyze the data, followed by Honestly Significance Difference using Minitab version 17.0. The result indicated a significant effect of PF, PFF, and metformin on decreasing FPG and MDA and increasing the number of pancreatic β- cells in DM rats. Porang flour (300 mg/kg bw) and middle-dose PFF are potential therapeutic agents for type-2 DM.